Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.

A 33-year-old male is starting treatment with oral dutasteride and topical minoxidil for hair regrowth. He is concerned about his receding hairline and hopes for some improvement despite years of balding.

The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.

PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

A 21-year-old male has been using minoxidil and 0.5 mg dutasteride for hair loss but is experiencing worsening hairline and thinning. He is considering increasing dutasteride dosage, adding finasteride, or waiting before opting for a hair transplant.

A 33-year-old man shares his one-year progress using 5% Minoxidil and 0.5% Tretinoin cream, along with derma stamping and specific shampoos, to combat hair thinning and promote hair growth. He avoids using finasteride or dutasteride, despite suggestions from others to try them for long-term maintenance.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A person had a hair transplant at Diamond Hair Clinic with Dr. Mehmet Demircioglu using the Sapphire FUE method with 4500 grafts. They are using Duasteride, oral and topical Minoxidil, and vitamins for recovery and hair growth.

A hair transplant surgery involving 3000 grafts and the daily use of oral finasteride and topical minoxidil for four months since that procedure.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

A user shared their positive experience with a hair transplant in Turkey using the DHI and Sapphire FUE techniques, without taking finasteride or minoxidil post-surgery. They emphasized that transplanted hairs from the donor area are resistant to hair loss, but acknowledged that native hairs might still thin without medication.

A 37-year-old male has been using finasteride for 5 years and dutasteride for 9 months to address hair loss, noticing improvements but also some recent thinning. He experienced no significant side effects from either treatment, except a slight decrease in semen volume with dutasteride, and is considering trying oral minoxidil again despite previous side effects.

A 45-year-old male experienced significant hair regrowth using 0.5 mg dutasteride and 1.5 mg minoxidil after initially starting with finasteride. He reports no major side effects, except increased hair growth in unwanted areas, and attributes his success to being a good responder to the medication.

The conversation discusses hair loss treatment progress using dutasteride 0.5 mg and oral minoxidil 5 mg. Users comment on the progress and inquire about side effects and additional photos.

A 24-year-old is using 1 mg oral dutasteride and 1 mg oral minoxidil daily, along with monthly mesotherapy including zinc, dutasteride, minoxidil, biotin, and panthenol, to treat hair loss. The user is considering increasing the minoxidil dose but will consult with their doctor first.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The user has been using 0.5 Dutasteride and 2.5 Oral Minoxidil for 5 months, along with The Ordinary Hair Serum, and is seeing gradual hair improvement. They skipped Finasteride due to severe hair loss and are considering a hair transplant if needed.

A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.

Dutasteride Mesotherapy for hair loss is discussed, noting its potential to lower scalp DHT without side effects. Concerns include the inconvenience of injections, lack of reputable studies, and availability issues.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

The user is considering a hair transplant and is using topical finasteride, minoxidil, antiandrogens, ketoconazole shampoo, and serenoa repens. They are deciding between surgeons Dogan Turan and Bruno Pinto, and are concerned about the technique and potential complications due to diffuse hair loss.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

Higher doses of dutasteride, such as 2.5mg, are more effective at reducing scalp DHT than 0.5mg, but are costly and inconvenient. A 1mg dose is considered a more affordable and practical option, though its efficacy is uncertain.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.